Novo Nordisk's third-quarter sales grew 6% to $11.9 billion

Statements (10 of 11)

1. ▲ Bullish

   Novo Nordisk has increased its forecast for Wegovy and Ozempic demand for the year.

   thewest.com.auNov 4, 2026 09:03 UTCHigh importance
2. ▲ Bullish

   Novo Nordisk has raised its full-year outlook for the third time this year.

   rte.ieNov 4, 2026 09:00 UTCHigh importance
3. ▲ Bullish

   Novo Nordisk raised its annual guidance following the continued rollout of Wegovy.

   wsj.comNov 4, 2026 08:41 UTCHigh importance
4. ▲ Bullish

   Novo Nordisk's operating income increased by 27% after excluding currency effects.

   wiwo.deNov 4, 2026 08:14 UTCHigh importance
5. ▲ Bullish

   Novo Nordisk reported third-quarter results that exceeded analyst expectations.

   portfolio.huNov 4, 2026 07:54 UTCHigh importance
6. ▲ Bullish

   Novo Nordisk raised its outlook for the full year.

   deraktionaer.deNov 4, 2026 07:11 UTCHigh importance
7. ▲ Bullish

   Novo Nordisk reported strong third-quarter results that exceeded analyst expectations.

   deraktionaer.deNov 4, 2026 07:11 UTCHigh importance
8. ▲ Bullish

   Novo Nordisk reported third-quarter sales of $11.9 billion for fiscal 2026.

   breakingthenews.netNov 4, 2026 06:33 UTCHigh importance
9. ▲ Bullish

   Novo Nordisk's third-quarter sales grew 6% compared to the same period in 2025.

   breakingthenews.netNov 4, 2026 06:33 UTCHigh importance
10. ▲ Bullish

    Novo Nordisk ticked up.

    247wallst.comOct 29, 2026 14:03 UTC

1 more statement on this development this week. The API returns all of them: GET /v2/statements?topic_id=9e914d00-eb06-451e-b7b7-dae1e88b91df Get a free API key ↗